Associated Papers
An additional site mutation in MITA/STING gain-of-function mutants abolishes the autoimmune SAVI phenotypes and directs a therapeutic strategy.
Li FX et al.
Cell Insight, 2026
STING: a multifaced player in cellular homeostasis.
Song K et al.
Human Molecular Genetics, 2025
Cell biological insights into human STING variants.
Koide S et al.
Cell Structure and Function, 2025
Mosaic TMEM173 gene mutation R284S leading to STING-associated vasculopathy with onset in infancy (SAVI).
Yang Z et al.
International Journal of Dermatology, 2025
A novel STING variant triggers endothelial toxicity and SAVI disease.
Valeri E et al.
The Journal of Experimental Medicine, 2024
Membrane traffic governs the STING inflammatory signalling.
Taguchi T
Journal of Biochemistry, 2023
Case report: JAK1/2 inhibition with baricitinib in the treatment of STING-associated vasculopathy with onset in infancy.
Wu J et al.
Pediatric Rheumatology Online Journal, 2023
Use of Tofacitinib for infant-onset STING-associated vasculopathy: A case report from China.
Shen D et al.
Medicine, 2022
Human STING Is Regulated by an Autoinhibitory Mechanism for Type I Interferon Production.
Qi S et al.
Journal of Innate Immunity, 2022
The activity of disease-causative STING variants can be suppressed by wild-type STING through heterocomplex formation.
Shindo R et al.
Frontiers in Cell and Developmental Biology, 2022
Case Report: Novel SAVI-Causing Variants in STING1 Expand the Clinical Disease Spectrum and Suggest a Refined Model of STING Activation.
Lin B et al.
Frontiers in Immunology, 2021
A novel STING1 variant causes a recessive form of STING-associated vasculopathy with onset in infancy (SAVI).
Lin B et al.
The Journal of Allergy and Clinical Immunology, 2020
Cryo-EM structures of STING reveal its mechanism of activation by cyclic GMP-AMP.
Shang G et al.
Nature, 2019
A case of STING-associated vasculopathy with onset in infancy with novel STING1 variant.
Barry KK et al.
Pediatric Dermatology, 0
Select a paper to view details